Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance.

In particular, no reliable history factor could predict the visual acuity change after switching, although the visual acuity change before switching almost reached statistical significance.

also in 378 other papers

In terms of CRT changes, there was a highly significant correlation between CRT change from Month 3 (post loading phase of ranibizumab) to the switch time point and CRT change during the 3-month period after switching to aflibercept ( R 2 =−0.47, p <0.0001).

also in 132,142 other papers